Oral News and Research

RSS

States: Texas GOP rift in primary; L.A. nursing homes scrutiny; Calif. health costs protest

A selection of health policy stories from Texas, California, Arizona, Wisconsin, Connecticut, Virginia and Georgia.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

Study to understand role of bacterium in heart valve disease

A disease-causing bacterium found in the mouth needs manganese, a trace mineral, in order to cause a serious heart infection, according to a preclinical study led by researchers at Virginia Commonwealth University Philips Institute for Oral Health Research in the School of Dentistry.

6 Mar 2014

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

5 Mar 2014

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Merck, known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego.

5 Mar 2014

Women using DMPA injection more likely to acquire HIV than women using NET-EN

Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.

5 Mar 2014

Neos Therapeutics completes private financing round, raises $15.5M

Neos Therapeutics, Inc. ("Neos" or "the Company"), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has completed an oversubscribed round of private financing, raising a total of $15.5 million.

4 Mar 2014

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2013.

4 Mar 2014

UNM physician performs TORS procedure on patient with stage IV throat cancer

When Charlie Guinn sits down to eat with his lovely wife of 39 years, he thoroughly enjoys each bite. It's not just the food; the entire experience is a celebration. Just over a year ago, Mr. Guinn learned that he had stage IV throat cancer.

4 Mar 2014

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.

4 Mar 2014

Majority of women experience reproductive coercion and intimate partner violence

Enough women experience reproductive coercion - male behavior to control contraception and pregnancy outcomes - that a research team now recommends health care providers address the subjects with their patients and tailor family planning discussions and recommendations accordingly.

4 Mar 2014

New minimally-invasive procedure to treat jackhammer esophagus

Six weeks ago 67-year old John Galbreath welcomed death, rather than live one more day. Intense pain in his chest had left him nearly bedridden for four months. Galbreath had a condition called jackhammer esophagus, which made him feel like the name suggests—like a jackhammer was going off in his chest.

4 Mar 2014

New approach to breast reconstruction surgery decreases use of postoperative opioid painkiller

A new approach to breast reconstruction surgery aimed at helping patients' bodies get back to normal more quickly cut their postoperative opioid painkiller use in half and meant a day less in the hospital on average, a Mayo Clinic study found.

4 Mar 2014

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its 2013 fourth quarter and full year ended December 31, 2013.

4 Mar 2014

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

TherapeuticsMD, Inc., a women's healthcare company, today announced results for the three-month period and full-year ended December 31, 2013.

4 Mar 2014

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.

3 Mar 2014

Oral News and Research

States: Texas GOP rift in primary; L.A. nursing homes scrutiny; Calif. health costs protest

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Study to understand role of bacterium in heart valve disease

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Women using DMPA injection more likely to acquire HIV than women using NET-EN

Neos Therapeutics completes private financing round, raises $15.5M

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

UNM physician performs TORS procedure on patient with stage IV throat cancer

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Majority of women experience reproductive coercion and intimate partner violence

New minimally-invasive procedure to treat jackhammer esophagus

New approach to breast reconstruction surgery decreases use of postoperative opioid painkiller

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

TherapeuticsMD's fourth quarter 2013 net revenue increases to $2.9 million

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Asthma drug accelerates desensitization in patients with food allergies to several foods

Valeant Pharmaceuticals total revenues up 109% in fourth quarter 2013

Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis

Researchers discover how byproducts from bacteria prevalent in gum disease incite growth of deadly tumors

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News